Andre-Jacques Auberton-Herve insider trades: Bionik Laboratories (BNKL) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andre-Jacques reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 9, 2023 | BNKL | ↑ Buy | 650,000 | $0.60 | $390K | Shares held through Star SCI | Jun 21, 2023 (12d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Andre-Jacques Auberton-Herve's insider trades
Andre-Jacques Auberton-Herve is a director at Bionik Laboratories (BNKL). Since Jun 9, 2023, Andre-Jacques has reported 1 open-market purchase worth $390K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include conversions (5 filings), grants and awards (4 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BNKL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.